drugset / Trial / NCT05969717
Induced Pluripotent Stem Cell Derived Exosomes for the Treatment of Atopic Dermatitis
Phase 0
Unknown
20 enrolled
Peking Union Medical College Hospital
Guidon Pharmaceutics Ltd. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Evaluate the safety, tolerability, and preliminary efficacy of GD-iExo-001 in the treatment of atopic dermatitis
Timeline
- Start
- 2023-04-12
- Primary completion
- 2025-04-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GD-iExo-001 | Unknown | 10 ug/ml | Topical |
| Subject | GD-iExo-001 | Unknown | 50 ug/ml | Topical |